Cargando…
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases
Autoimmune systemic diseases (ASD) show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed at evaluating the seroconversion elicited by COVID-19 vaccine over the entire vaccination cycle including the booster dose. Among 478 unselected ASD patients or...
Ejemplares similares
-
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups
por: Ferri, Clodoveo, et al.
Publicado: (2021) -
COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies
por: Gragnani, Laura, et al.
Publicado: (2022) -
COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity
por: Gragnani, Laura, et al.
Publicado: (2023) -
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase
por: Ferri, Clodoveo, et al.
Publicado: (2023) -
Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study
por: La Gualana, Francesca, et al.
Publicado: (2023)